Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.92
HZNP's Cash to Debt is ranked higher than
60% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. HZNP: 0.92 )
HZNP' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.92

Equity to Asset -0.77
HZNP's Equity to Asset is ranked lower than
59% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. HZNP: -0.77 )
HZNP' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.7
Current: -0.77

-0.77
0.7
F-Score: 3
Z-Score: -4.85
M-Score: 0.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -57.90
HZNP's Operating margin (%) is ranked lower than
51% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. HZNP: -57.90 )
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5   Max: -57.9
Current: -57.9

-1841.5
-57.9
Net-margin (%) -201.31
HZNP's Net-margin (%) is ranked lower than
54% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. HZNP: -201.31 )
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12   Max: -201.31
Current: -201.31

-1635.12
-201.31
ROA (%) -58.99
HZNP's ROA (%) is ranked lower than
55% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. HZNP: -58.99 )
HZNP' s 10-Year ROA (%) Range
Min: -249.6   Max: -16.74
Current: -58.99

-249.6
-16.74
ROC (Joel Greenblatt) (%) -1133.70
HZNP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. HZNP: -1133.70 )
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7948.82   Max: -1133.7
Current: -1133.7

-7948.82
-1133.7
Revenue Growth (%) -14.60
HZNP's Revenue Growth (%) is ranked higher than
50% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. HZNP: -14.60 )
HZNP' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -14.6
Current: -14.6

EBITDA Growth (%) -74.50
HZNP's EBITDA Growth (%) is ranked lower than
56% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. HZNP: -74.50 )
HZNP' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -74.5
Current: -74.5

EPS Growth (%) -52.00
HZNP's EPS Growth (%) is ranked lower than
51% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. HZNP: -52.00 )
HZNP' s 10-Year EPS Growth (%) Range
Min: 0   Max: -52
Current: -52

» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

HZNP Guru Trades in Q3 2012

Columbia Wanger 1,290,000 sh (-7.53%)
» More
Q4 2012

HZNP Guru Trades in Q4 2012

Columbia Wanger Sold Out
» More
Q4 2013

HZNP Guru Trades in Q4 2013

Paul Tudor Jones 14,646 sh (New)
Jim Simons 358,000 sh (New)
» More
Q1 2014

HZNP Guru Trades in Q1 2014

Paul Tudor Jones 16,733 sh (+14.25%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HZNP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 7.70
HZNP's P/S is ranked higher than
58% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. HZNP: 7.70 )
HZNP' s 10-Year P/S Range
Min: 1.47   Max: 19.46
Current: 7.7

1.47
19.46
EV-to-EBIT -46.03
HZNP's EV-to-EBIT is ranked higher than
50% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. HZNP: -46.03 )
HZNP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -46.03

Current Ratio 2.34
HZNP's Current Ratio is ranked higher than
70% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. HZNP: 2.34 )
HZNP' s 10-Year Current Ratio Range
Min: 0.16   Max: 4.39
Current: 2.34

0.16
4.39
Quick Ratio 2.21
HZNP's Quick Ratio is ranked higher than
75% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. HZNP: 2.21 )
HZNP' s 10-Year Quick Ratio Range
Min: 0.16   Max: 4.27
Current: 2.21

0.16
4.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.80
HZNP's Price/Median PS Value is ranked higher than
60% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. HZNP: 1.80 )
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 3.73
Current: 1.8

0.37
3.73

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPM.Germany
Horizon Pharma Inc is a specialty pharmaceutical company. It has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
HORIZON PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jul 02 2014
Walgreen 3Q profit jumps but misses expectations Jun 24 2014
HORIZON PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 19 2014
Horizon Pharma Announces Execution of $300 Million Senior Secured Credit Agreement in Connection... Jun 19 2014
HORIZON PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jun 18 2014
Horizon Pharma Announces Robert J. De Vaere to Retire and Names Paul W. Hoelscher Chief Financial... Jun 18 2014
Horizon Pharma to Present at the JMP Securities Healthcare Conference 2014 Jun 17 2014
Horizon Pharma: Can It Double Again? Jun 16 2014
U.S. Companies Catch World Cup Fever with Foreign Mergers Jun 16 2014
Why Horizon Pharma (HZNP) Could Be Positioned for a Surge? Jun 11 2014
Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jun 06 2014
Horizon Pharma (HZNP) Stock Has Huge Short Interest: Time to Cover? Jun 02 2014
Substance Over Style: How Niche Companies Alliqua And Horizon Are Being Overlooked May 29 2014
Horizon Pharma (HZNP): An Off-the-Radar Potential Winner May 29 2014
Horizon Pharma to Present at the Jefferies 2014 Global Healthcare Conference May 27 2014
Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 23 2014
AstraZeneca's Rejection Shows Stakes Are High for Inversion Deals May 19 2014
HORIZON PHARMA, INC. Financials May 16 2014
Options with decreasing implied volatility: NQ HZNP UBNT GMCR May 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide